Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$5.2 million.

  • vTv Therapeutics' Cash from Operations rose 1863.51% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.8 million, marking a year-over-year increase of 1097.2%. This contributed to the annual value of -$25.3 million for FY2024, which is 3262.93% down from last year.
  • As of Q3 2025, vTv Therapeutics' Cash from Operations stood at -$5.2 million, which was up 1863.51% from -$5.1 million recorded in Q2 2025.
  • vTv Therapeutics' 5-year Cash from Operations high stood at $706000.0 for Q2 2022, and its period low was -$8.8 million during Q3 2022.
  • Over the past 5 years, vTv Therapeutics' median Cash from Operations value was -$5.2 million (recorded in 2025), while the average stood at -$5.0 million.
  • As far as peak fluctuations go, vTv Therapeutics' Cash from Operations surged by 11765.88% in 2022, and later crashed by 97351.27% in 2023.
  • Quarter analysis of 5 years shows vTv Therapeutics' Cash from Operations stood at -$6.4 million in 2021, then fell by 7.22% to -$6.9 million in 2022, then skyrocketed by 57.65% to -$2.9 million in 2023, then plummeted by 65.58% to -$4.8 million in 2024, then dropped by 8.23% to -$5.2 million in 2025.
  • Its Cash from Operations was -$5.2 million in Q3 2025, compared to -$5.1 million in Q2 2025 and -$5.7 million in Q1 2025.